Tags: Clinical Trials

blog

Two Decades of Research: The ADDF's 19th International Conference on Alzheimer’s Drug Discovery

Last week, researchers gathered at our annual conference to share updates on their approaches to develop Alzheimer's treatments.

announcements

Dr. Michela Gallagher Wins Alzheimer's Drug Discovery Foundation's Prestigious Goodes Prize

Michele Gallagher, PhD, is the recipient of the fourth Melvin R. Goodes Prize, which includes a $150,000 award to support the therapeutic development of AGB-101.

announcements

$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments

The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.

announcements

New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction

The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.

announcements

$2.5 Million in New Funding Exemplifies ADDF’s Strategy

We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease. 

blog

Alzheimer’s Clinical Trials, Explained

Learn about clinical trials, an important and growing part of our funding at the Alzheimer’s Drug Discovery Foundation. 

blog

ADDF Grantees Headline NIH Alzheimer's Summit

ADDF-supported research was at the forefront of the Summit and the National Plan to Address Alzheimer's.

blog

Meeting the Challenge of CTE

For CTE Awareness Day, we highlight our support of diagnostic tools and treatments for this disease. 

announcements

$1.8 Million in New Funding Supports Clinical Stage Treatments

The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.

blog

Top Five Alzheimer’s Advances in 2017

Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.